Logo
Logo

探索 中枢神经系统 (CNS) Products

阿普斯特(无定型及晶型B)

中枢神经系统 (CNS)

盐酸托莫西汀

中枢神经系统 (CNS)

甲磺酸苯扎托品

中枢神经系统 (CNS)

富马酸二甲酯

中枢神经系统 (CNS)

盐酸多奈哌齐

中枢神经系统 (CNS)

依达拉奉

中枢神经系统 (CNS)

醋酸艾斯利卡西平

中枢神经系统 (CNS)

艾司佐匹克隆

中枢神经系统 (CNS)

左乙拉西坦

中枢神经系统 (CNS)

对甲苯磺酸卢美哌隆

中枢神经系统 (CNS)

盐酸鲁拉西酮

中枢神经系统 (CNS)

盐酸美金刚

中枢神经系统 (CNS)

普瑞巴林

中枢神经系统 (CNS)

Rimegepant

中枢神经系统 (CNS)

利培酮

中枢神经系统 (CNS)

重酒石酸卡巴拉汀

中枢神经系统 (CNS)

罗匹尼罗

中枢神经系统 (CNS)

西尼莫德

中枢神经系统 (CNS)

舒更葡糖钠

中枢神经系统 (CNS)

盐酸替扎尼定

中枢神经系统 (CNS)

Xanomeline

中枢神经系统 (CNS)

盐酸齐拉西酮一水合物

中枢神经系统 (CNS)

Fluoxetine

中枢神经系统 (CNS)

富马酸喹硫平

中枢神经系统 (CNS)

USPs of our CNS APIs

  • Firm PSD control to help maintain consistency of manufacturing process.
  • Sufficient capacity to meet our customer’s global leadership requirements.
  • Reliable KSM suppliers in India with timely deliveries and stringent specifications.
  • IP compliant process.
  • Well-controlled all the plausible impurities within the specified limit.
  • Commercially available starting materials.
  • Schemes of starting material evaluated.
  • Flexible business models to support registrations.
  • Adequate capacity available to supply development quantity in short lead time.
  • Free from nitrosamine impurities.
  • QBD (Quality by Design) based API development for consistent quality profile.
  • Continuous improvement in place to achieve cost and quality excellence.
  • Process safety and scalability.
  • APIs suitable for global formulation development.
  • Fully backward integration process.
  • Compliant to all pharmacopeia’s.
  • Multiple domestic sources for KSMs available.
  • Able to match a wide range of particle size requirements.

Get access to Dr. Reddy's largest CNS API portfolios to support your formulation success

Dr. Reddy’s is one of the leading generic pharmaceutical companies and CNS API suppliers in the development and manufacturing of CNS APIs used in formulations to treat indications in the central nervous system (CNS) therapy area. Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.

探索 other Therapeutic categories.

CNS -FAQ

What is the Central Nervous System API drug classification?
  • Our CNS API product portfolio is broad-based, including APIs in the class of atypical antipsychotics, anticholinergics, Nrf2 activators, cholinesterase inhibitors, antioxidants, and GnRH antagonists.

What is the mechanism of action for Central Nervous System APIs?
  • They can act either as neurotransmitter agonists, such as the opioids, which mimic the action of enkephalin, or they can block receptor function. Receptor antagonism is a common mechanism of action for CNS drugs.

What is the global market for Central nervous system drugs?
  • The global central nervous system therapeutic market was valued at 116.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.4% from 2021 to 2028. Advancements in diagnostics and therapeutics of CNS diseases are expected to increase the treatment rate globally.

What are the uses for Central Nervous System APIs?
  • Used to treat insomnia (trouble sleeping), anxiety, panic attacks, and seizures. They may also be used to relieve anxiety and tension before surgery. Examples of CNS depressants are benzodiazepines, barbiturates, and certain sleep medicines.

免责声明

本網站上的任何信息,包括對任何產品或服務的任何提及,均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是,在某些情況下,雷迪博士可自行決定並根據當地法律要求,在存在此類監管豁免的任何地方,提供此類產品的研究數量,以根據《印度專利法》第 107A 條(Bolar 豁免)進行監管提交。購買者應對其各自市場的產品或服務(包括專利情況)進行獨立評估,並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證,包括但不限於適銷性、適用於特定用途和非侵權的保證。

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.